Lazard Asset Management
FNCH

Lazard Asset Management’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Lazard Asset Management’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5
Closed -$1K – 2594
2021
Q4 		$1K Buy
+5
New +$1.92K ﹤0.01% 2261

Other funds holding FNCH

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
LSCM
Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return
TA
TRB Advisors New York $146M AUM 3.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Lazard Asset Management's FNCH Position: Q1 2022 in Review

Lazard Asset Management sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q1 2022, closing a stake of 5 shares — an estimated $1K sold.

Lazard Asset Management first reported a position in FNCH in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 53 funds tracked by Wall St. Rank hold FNCH as of Q1 2022.

  • Lazard Asset Management reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Lazard Asset Management sold 5 Finch Therapeutics Group, Inc. Common Stock shares in Q1 2022, an estimated $1K.
  • Lazard Asset Management first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Lazard Asset Management's Finch Therapeutics Group, Inc. Common Stock position peaked at $1K in Q4 2021.
  • 53 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q1 2022.

Based on Lazard Asset Management's 13F filing for Q1 2022, filed 13 May 2022.